IL2 and nonpapillary renal cell carcinoma: Interestingly, most relevant to immunotherapeutic response are the upregulation of the IL-2 STAT5 signaling pathway and the downregulation of the mTORC1 signaling pathway, both have long been applied in systemic ccRCC treatment.